Crescent Biopharma, Inc. (NASDAQ:CBIO – Free Report) – Wedbush issued their Q2 2025 earnings estimates for shares of Crescent Biopharma in a research report issued on Monday, July 14th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will earn ($0.76) per share for the quarter. Wedbush has a “Outperform” rating and a $27.00 price target on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($0.16) per share. Wedbush also issued estimates for Crescent Biopharma’s Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.30) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($6.38) EPS, FY2028 earnings at ($4.54) EPS and FY2029 earnings at ($4.48) EPS.
A number of other equities research analysts have also weighed in on the company. Stifel Nicolaus began coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They set a “buy” rating and a $28.00 price objective on the stock. TD Cowen upgraded Crescent Biopharma to a “strong-buy” rating in a report on Friday, June 20th. Lifesci Capital raised Crescent Biopharma to a “strong-buy” rating and set a $22.00 price objective for the company in a research note on Wednesday, June 18th. Finally, Wall Street Zen upgraded shares of Crescent Biopharma to a “sell” rating in a research report on Saturday, July 12th. One analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.67.
Crescent Biopharma Price Performance
Shares of NASDAQ:CBIO opened at $13.14 on Wednesday. Crescent Biopharma has a 52-week low of $11.06 and a 52-week high of $63.00. The firm has a market cap of $256.89 million, a PE ratio of -0.29 and a beta of 1.52.
About Crescent Biopharma
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Further Reading
- Five stocks we like better than Crescent Biopharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Stocks to Cushion Your Portfolio This Earnings Season
- Investing in Commodities: What Are They? How to Invest in Them
- This Fund Manager Says You Should Get Out of Tesla and Apple—Now
- How to Short Nasdaq: An Easy-to-Follow Guide
- JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
